Stephanie Neville’s Post

Investment Brief UnivLabs Technologies Pvt Ltd 👉 Introduction: UnivLabs is a pioneering medical devices company entering an exciting growth phase, marked by cutting-edge innovation, a robust intellectual property portfolio, and real-world manufacturing capabilities. With a strong foundation in research and a focus on practical, scalable solutions, UnivLabs is poised to redefine the future of healthcare technology. 👉 Key Highlights • Exponential Growth: UnivLabs is on track to achieve a 7x revenue increase compared to the past two years, fueled by expanding markets and breakthrough products. • Innovation-Driven: Backed by proprietary technologies and patents, UnivLabs ensures sustainable competitive advantages in the medical devices sector. • Global Presence: Research and Development offices in India and Europe provide a strategic edge, combining cost-effective innovation with access to global expertise. • Manufacturing Excellence: UnivLabs boasts in-house manufacturing, ensuring quality control and scalability to meet growing market demands. 👉 Market Opportunity: The global medical devices market is projected to grow at a CAGR of 5-6%, with increasing demand for high-quality, affordable healthcare solutions. UnivLabs addresses this demand by delivering innovative products across diagnostics, surgical equipment, and other essential medical technologies. 👉 Investment Rationale: 1. Proven Track Record: UnivLabs has demonstrated consistent growth, backed by successful product launches and market penetration. 2. Scalable Model: The company is strategically positioned to expand its footprint in emerging and developed markets, leveraging its R&D and manufacturing capabilities. 3. High Growth Potential: With a robust pipeline of products and a focus on underserved medical needs, UnivLabs offers significant upside for investors. 4. Sustainability: UnivLabs integrates innovation with affordability, ensuring long-term relevance in a competitive industry. 👉 Call to Action: UnivLabs is inviting strategic investors to partner in this growth journey, fueling the next phase of innovation, market expansion, and value creation. Your investment will support not only our vision to revolutionize healthcare but also deliver exceptional returns in a rapidly growing sector. For further discussions, please reach out to vivek@univlabs.in #InvestInInnovation #Startup #HealthcareRevolution #MedTechGrowth #ScalingHealthcare #VCOpportunities #FutureOfMedTech #InnovationDriven #MedicalDevicesStartup #GrowthPhaseInvesting #GlobalHealthTech #Startupfunding #PrivateEquity

The MedTech innovation ecosystem was on full display at LSI USA Conference this week. The current RIGOROUS quality, clinical, regulatory and commercial environment requires MedTech companies to reimagine innovation. The quality of partners is critical, and the capabilities they bring will determine success. A few key takeaways: 1. Virtual twins are already in the EP Lab with sentiar and others. Virtual Twins have the potential to transform patient care and the physician experience. Get in the flow of data! 2. Developing early and late stage clinical evidence is key to commercial success. Use clinical trial partners who have the experience because experience matters. 3. The decision to acquire pre-revenue assets is risky but can be rewarding. It was refreshing to hear the agonizing (sometimes exhilarating) stories of some of the most innovative technologies that transform patient lives - Ardian, Watchman, Libre, among others. 4. Deals will die if the quality work required to plug into the big strategic quality system is too high! No one wants to spend $10M each year for 3 years! 4. There is agony in killing MedTech products that don’t have long term viability - kill them anyway, fail fast and move on! 5. There is such a need for equity & access - to care, to funding, to resources, to opportunities - let’s do better! Thank you Bill Colone and Maria Colone for sharing on this journey. Medidata Solutions Dassault Systèmes Maria Artunduaga, MD, MPH, MTM Sanna Gaspard, PhD Elizabeth Clayborne, MD, MA Jill Hadel Ravjeet Sandher Astride Tchoffo Rick Satcher Benjamin Lewis Lishan Aklog, MD

The top 5 largest investment deals in MedTech startups worldwide. According to Becker's Hospital Review, here are the top 5 largest investment deals in 2023: 1. Neuralink led the pack with a whopping $280 million raised in their Series D funding round, making waves in the brain-computer interface sector. 2. ShiftMed secured $200 million in funding, enhancing digital health recruitment solutions. 3. Arcadia soared with $125 million in investment for their innovative medical data analysis platform. 4. MedShift received $108 million to bolster corporate solutions for medical device manufacturers. 5. Artera rounded out the top 5 with $90 million in financing for their AI-driven malignancy detection tools. These investments showcase the immense potential and growth opportunities in the global digital health and medical technology market. #otexe #otexedigest

Project Medtech Midwest - Chicago - May 8th I'm looking forward to speaking at the Project Medtech Midwest Showcase on May 8th. It is always great to connect with fellow investors and the early stage company CEOs that are looking for capital for their medical technologies. Here is a link for additional information on the event:   https://lnkd.in/g9-p2FVe #medtech #medicaldevices #medicaltechnology #projectmedtech #innovation "

From Hospital Innovation to Startup Success Great medtech ideas often begin in the hospital—where clinicians see firsthand what patients need. But turning those ideas into a thriving business? That’s where Merge | Medical Device Studio comes in. At Merge, we help hospitals and clinicians take those innovations from concept to reality: - First designs and prototypes to showcase the idea - Business plans that prepare your idea for licensing or funding - Team building to ensure you have the right talent to drive the project Whether you're working on a device that addresses an unmet clinical need or looking to spin out a new technology into a startup, we help you navigate the journey from concept to clinical use. 💡 Ready to take your innovation to the next level? Let’s talk.

One day we will have access to universal medicine, just as iPhones are sold globally. This sentence encapsulates the current challenges, possibilities, and policy-making in our pharma, healthcare and life. industry. I spent the first half of the week in Basel attending Swiss Biotech Day, with the highlight being the Capital for Cures Summit! Many of us were eager to leave 2023 behind, but let's consider 2024 as a beacon of new hope for M&A and financing to make a strong comeback. Now is the time to focus on genuine innovation, cutting-edge research, and the development of new biotech products. Although fundraising may present challenges, it's important to remember that every challenge has a silver lining. Here are a few areas where to focus in 2024: -Big Picture and Synergies: How startups and early-stage companies can leverage synergies with other portfolio companies to foster international collaborations. By strengthening global partnerships and exploring new financial models and funding mechanisms aiming to create a robust "Global Village." -Advanced R&D and Manufacturing: Being committed to enhancing research and product development with advanced manufacturing techniques. -Data Management and AI: Integrating artificial intelligence and comprehensive data management systems to boost research outputs and operational efficiencies. -Innovative Financing Exploring innovative financial models and funding mechanisms to support the sustainable growth of biotech ventures.   It was fantastic to present SS&C Intralinks and share the panel with Alan Crowther Marcus Guardian, and Eric de La Fortelle A special shout-out to Sebastian Gensior for making this possible!

Latest DON Therapeutics News The medtech industry, particularly the medical device sector, is experiencing a period of rapid transformation and growth. As one of the most innovative fields, it is at the forefront of technological advancements that have the potential to completely revolutionize global healthcare. These innovations are not only enhancing the quality and efficiency of medical treatments but also fundamentally changing the way individuals interact with and manage their own health. From wearable health monitors that provide real-time data to advanced diagnostic tools that enable early detection of diseases, medical devices are making healthcare more personalized and accessible. This transformation is fostering a more proactive approach to health management, empowering individuals to take control of their well-being in unprecedented ways. For emerging companies and investors, the medtech industry presents a unique opportunity. The demand for innovative medical solutions is growing, driven by an aging global population, increasing prevalence of chronic diseases, and a heightened focus on preventative care. This burgeoning market offers a fertile ground for investment and innovation, with the potential for significant financial returns and the ability to make a profound impact on global health. More about DON Therapeutics: https://lnkd.in/eKs-9g9e We are always looking for new healthcare opportunities. Submit your opportunity: https://lnkd.in/dJfhwVvv #funding #biotechnology #medtech #startups #investors

If you're interested in medtech innovations, you might want to tune into the Deals over Dinner event on Sunday, January 26th - 6pm. Oleg Gusyatin from Macula Vision Systems is set to introduce us to a pretty exciting piece of tech. Macula Vision has developed a prototype for an AI-powered microscope designed to change how microbiological tests are analyzed. Why should we pay attention? - There's a real problem with the current process of analyzing the 200 million Gram stains done every year in the U.S. It's mostly manual, needs staffing, or uses expensive devices that take ages. - Macula Vision's solution? A low-cost device that simplifies purchasing decisions for lab managers. Its automated system speeds up the process, making labs more economically efficient while staying within reimbursement codes. - They're using a "Medical Device as a Service" model, much like SaaS, promising the same kind of economic benefits and values. The team behind this is not just any random group—they've got a track record of developing and getting approvals for medical devices. Plus, their innovation hasn't gone unnoticed—they've won awards like the DxPx US Startup Award 2024 and have received significant grants for their work. If you're an angel investor or just someone who's interested in how AI can transform healthcare diagnostics, you should definitely check this out. It's a chance to hear directly from Oleg about why this technology has great exit potential. And, why not enjoy some Spanish tapas and good wine while you're at it? If you're curious, you can register for the event at SLS Angels' website. It's a laid-back way to connect with fellow investors and innovators while learning something worthwhile.

Medical technology (#Medtech) startups have one of the highest failure rates, some estimates as high as 98%. Why? Statistics point to lack of focus on commercialization. This is due to a lack of experience building appropriately diverse management teams with experience in integrating the many facets of the medical technology industry including: product design & development, financial considerations from funding to cost of goods sold, corporate governance, cap tables, critical regulatory milestones and compliance, realistic size of markets and critical unmet needs, key triggers for adoption, reimbursement options, and milestones critical to both the operational team and investors. Please register here: https://lnkd.in/egm7Y772?

Unlocking Innovation in MedTech: The Power of Digital Twins 🚀 Amidst the fast-paced advancements in #MedicalTechnology, innovation is key to delivering better patient outcomes and efficient product development. #DigitalTwins. These virtual replicas of real-world systems with substantial investments projected to reach $48.2 billion by 2026 are revolutionizing industries, including #MedTech. 🔍 Digital twins offer unprecedented value across the entire product lifecycle, from #R&D to #ClinicalTrials. In the MedTech sector, companies are realizing significant benefits, including enhanced product performance, reduced development costs, and accelerated time-to-market by 20-50%. These advancements extend to clinical trials, where costs are cut by up to 75%, resulting in faster and safer outcomes. Imagine a digital twin of the human liver being used to test drug efficacy or optimize medical devices—this is no longer a distant future but a present reality. Despite these exciting advancements, adoption in MedTech is still in its early stages. Barriers such as limited data availability, insufficient digital capabilities, and data privacy concerns continue to pose challenges for many in the industry. Overcoming these obstacles requires a strategic approach focused on developing agile delivery models and leveraging strong data foundations. Additionally, companies should build the necessary capabilities by starting with high-impact use cases and fostering a test-and-learn culture. 💡 The future of MedTech innovation is here. Will you be a leader or a latecomer? 💥 It’s time for MedTech companies to seize this opportunity and drive the next wave of innovation. 🔗 Learn more about how digital twins are reshaping MedTech: https://lnkd.in/dx5Nfpkh #MedTech #DigitalTwins #HealthcareInnovation #DigitalTransformation #Innovation #PersonalizedMedicine #MedicalTechnology #AgileDevelopment #HealthcareFuture